Nuage Therapeutics has appointed Judit Anido as CEO of the company to lead its growth and support the development of drugs that modulate therapeutic targets currently considered undruggable, in order to to improve patients’ lives.

Judit Anido is a healthcare entrepreneur and executive with an extensive  international experience in leading the activity of biotech companies up to  clinical phases. She founded and led as CEO the growth of Mosaic Biomedicals, a company focused on the development of innovative personalized treatments for cancer patients. In 2016, after the merger of Mosaic with the Canadian company Northern Biologics, Judit served as VP of Operations and Corporate Affairs at Northern. The clinical-phase drug developed by Mosaic, MSC-1, was acquired in 2020 along with the preclinical programs of the business conglomerate. Judit was also the President and CEO of CataloniaBio & HealthTech.

“The pioneer science developed by Nuage allows for the first time to understand the behaviour of therapeutic targets that due to their disordered domains were considered undruggable. This knowledge allows Nuage to develop targeted drugs that efficiently block such targets” says Judit Anido.

Judit Anido holds a PhD in Cancer Biology from the University of Barcelona (UB) and has an MBA from Duke University with specialization in health management, entrepreneurship, and innovation.

“Our goal is to transform Nuage recent discoveries on the structural and functional properties of biomolecular condensates into drugs that provide new treatment options for cancer patients, and Judit has the experience and expertise that perfectly complements the team to achieve this goal” says Dr Xavier Salvatella.

Nuage Therapeutics was founded in 2021 by IRB Barcelona, ICREA and the renowned researchers in the field of biomolecular condensates and intrinsically disordered proteins Xavier Salvatella, Mateusz Biesaga and Denes Hnisz, and has the financial support of Sabadell Asabys.